|
Expression and clinical features of hK members in ovarian cancer |
||||
| hK family member |
Location |
Expression level and site |
Clinical feature |
Prognosis |
|
|
||||
| hK4 |
Tumor cells |
Increased in EOC tissue |
Predictive marker for paclitaxel resistance[22] |
Unfavorable |
| hK5 |
Serum, ascites, and tumor extracts [23, 24] |
Increased on tumor cells and in serum and ascites |
Potential biomarker for diagnosis |
Unfavorable |
| hK6 |
Tumor cell[26] and serum[25] |
High in early-stage and low-grade tumor tissue and in EOC serum |
Overexpression is an early phenomenon in the development of ECO; serum level could be used as a biomarker |
Unfavorable |
| hK7 |
Tumor tissue[27] |
High in late-stage EOC |
A potential biomarker for diagnosis |
Unfavorable |
| hK8 |
Tumor extract, serum, and ascites[29] |
High in serum and ascites |
High level is associated with good prognosis[28, 29] |
Favorable |
| hK9 |
Tumor cells[30] |
High in tumor tissue early-stage and optimal debulking patients |
Associated with longer progression-free and overall survival times |
Favorable |
| hK10 |
Serum[33] and tumor cells[31,32] |
High in serum and on tumor cells |
High serum level is associated with increased risk for relapse and death; a potential biomarker for diagnosis |
Unfavorable |
| hK11 |
Serum, ascites[37], and tumor extract [34-36] |
Increased in tumor samples |
High level is an independent factor for favorable prognosis and is associated with long progression-free and overall survival times and with slower disease progression[34, 35]; however, high level is also associated with poor survival rate[36]. |
Depends |
| hK13 |
Tumor tissue[38] |
verexpressed in tumor tissue |
Associated with longer progression-free and overall survival times |
Favorable |
| hK14 |
Tumor cells[41] and serum[40] |
Increased in tumor tissue and serum |
Associated with longer progression-free and overall survival times; an independent prognostic factor |
Favorable |
| hK15 |
Tumor extract[42] |
Increased in tumor tissue |
Associated with short progression-free and overall survival times; an independent prognostic factor |
Unfavorable |
Wang et al. Journal of Translational Medicine 2005 3:25 doi:10.1186/1479-5876-3-25 |
||||